Chang SM, Yan ST, Wei CK, Lin CW, Tseng CE. Solitary concomitant endocrine tumor and ductal adenocarcinoma of pancreas. World J Gastroenterol 2010; 16(21): 2692-2697
Corresponding Author of This Article
Chih-En Tseng, MD, Department of Anatomic Pathology, Buddhist Dalin Tzu Chi General Hospital, 2, Min-Sheng Road, Dalin, Chiayi 622, Taiwan, China. firstname.lastname@example.org
Article-Type of This Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Shu-Mei Chang, Chih-En Tseng, Department of Anatomic Pathology, Buddhist Dalin Tzu Chi General Hospital, Chiayi 622, Taiwan, China
Shih-Tang Yan, Department of Endocrinology and Metabolism, Buddhist Dalin Tzu Chi General Hospital, Chiayi 622, Taiwan, China
Chang-Kuo Wei, Department of General Surgery, Buddhist Dalin Tzu Chi General Hospital, Chiayi 622, Taiwan, China
Chih-Wen Lin, Department of Medical Imaging, Buddhist Dalin Tzu Chi General Hospital, Chiayi 622, Taiwan, China
Chih-En Tseng, School of Medicine, Tzu Chi University, Hualien 97004, Taiwan, China
Author contributions: Chang SM and Tseng CE designed this study, drafted, revised the manuscript and made the final approval of the version; Yan ST, Wei CK and Lin CW collected, analyzed and interpreted the data.
Supported by Buddhist Dalin Tzu Chi General Hospital
Correspondence to: Chih-En Tseng, MD, Department of Anatomic Pathology, Buddhist Dalin Tzu Chi General Hospital, 2, Min-Sheng Road, Dalin, Chiayi 622, Taiwan, China. email@example.com
Telephone: +886-5-2648000 Fax: +886-5-2648999
Received: February 16, 2010 Revised: March 25, 2010 Accepted: April 1, 2010 Published online: June 7, 2010
Pancreatic tumors with combined exocrine and endocrine features are rare. Most reported cases are classified as mixed exocrine and endocrine carcinoma of the pancreas. We report the first case of solitary concomitant endocrine tumor and ductal adenocarcinoma of the pancreas. A 58-year-old patient was admitted for uncontrolled diabetes mellitus and body weight loss. The tumor was fortuitously discovered in the pancreatic tail after a tumor survey panel. Grossly, the solitary tumor had a central fibrous band that clearly divided it into two parts. On microscopic examination, the tumor contained both endocrine and exocrine components distinctly separated by the central fibrous band. The exocrine part showed a poorly-differentiated adenocarcinoma. The endocrine part was strongly immunoreactive to chromogranin, synaptophysin and glucagon. We reviewed the literature on pancreatic tumors with combined exocrine and endocrine features. A simple classification for this group of neoplasms is suggested, including five types: amphicrine, mixed, collision, solitary concomitant and multiple concomitant.
Citation: Chang SM, Yan ST, Wei CK, Lin CW, Tseng CE. Solitary concomitant endocrine tumor and ductal adenocarcinoma of pancreas. World J Gastroenterol 2010; 16(21): 2692-2697
Pancreatic tumors, categorized according to exocrine and endocrine origin, are classified into ductal, acinar or endocrine types by morphological and immunohistochemical studies. Pancreatic endocrine tumor (PET) is uncommon and represents only 1%-2% of all pancreatic tumors. Pancreatic exocrine tumor is rarely associated with pancreatic endocrine tumor. Most reported cases are mixed ductal-endocrine carcinoma, mixed acinar-endocrine carcinoma and mixed ductal-acinar-endocrine carcinoma[2-7]. These reported cases are classified according to World Health Organization (WHO) criteria, in which mixed exocrine and endocrine carcinoma is defined as carcinoma containing intimately intermixed exocrine and endocrine components, and each component comprises at least one-third of the tumor tissue. By this definition, a solitary concomitant pancreatic tumor with distinctly separated exocrine and endocrine components cannot be classified as mixed exocrine and endocrine carcinoma. Here, we report a case of solitary concomitant endocrine tumor and ductal adenocarcinoma of the pancreas. This type of pancreatic tumor is especially rare and, to the best of our knowledge, has never been reported in the English literature.
A 58-year-old Chinese male was admitted to the endocrinology and metabolism ward in July 2009 for poorly controlled hyperglycemia, which was refractory to an oral hypoglycemic agent. He had a history of diabetes mellitus (DM), hypertension and chronic renal insufficiency for more than 4 years and had been receiving regular follow-up at the outpatient clinic of this hospital. On admission, laboratory test (Table 1) revealed that his blood glucose was 561 mg/dL. Physical examination showed no skin rash or oral lesions. While he was hospitalized, daily high-dose insulin injection with Novomix 60 U/d was necessary to control his blood glucose level. The patient also complained of losing 10 kg of body weight in the prior two months. Therefore, he asked for a tumor marker examination. A tumor survey panel revealed an elevated carbohydrate antigen 19-9 (CA19-9) of 195 U/mL (normal, 0-37 U/mL) incidentally. Abdominal computed tomography (CT) demonstrated a 3.7 cm × 2.1 cm tumor in the pancreatic tail (Figure 1) and unremarkable adrenal glands bilaterally. Whole body positron emission tomography showed moderately increased accumulation of fluorine-18 fluorodeoxyglucose (F-18 FDG) in the pancreatic tail with standard uptake values of 3.3 (initial) and 4.5 (delayed). No increased uptake in other organs or sites was identified. Thyroid ultrasound showed no focal lesion. The patient received distal pancreatectomy and splenectomy under the impression of pancreatic tail carcinoma. Neither liver metastasis nor peritoneal seeding was found during surgery. The postoperative course was uneventful. Initially, only an oral hypoglycemic agent was prescribed for controlling DM when the patient was discharged from the hospital. However, because hyperglycemia (268 mg/dL) and elevated glycosylated hemoglobulin HbA1c (8.1%) were found at follow-up in the outpatient clinic, insulin injection with Novomix 28 U/d was represcribed. The patient moved to another city for family support and admitted there one month after operation. Therefore we lost the follow-up of him.
Normal values: CA19-9: 0-37 U/mL; AFP: 0-10 ng/mL; CEA: 0-7 ng/mL; PSA: 0-4 ng/mL. CBC and DC: Complete blood cell count and differential count; WBC: White blood cell count; RBC: Red blood cell count; BUN: Blood urea nitrogen; CA19-9: Carbohydrate antigen 19-9; AFP: α-fetoprotein; CEA: Carcinoembryonic antigen; PSA: Prostate-specific antigen.
Figure 1 Computed tomography (CT) scan demonstrating a 3.
7 cm × 2.1 cm tumor (arrow) in pancreatic tail.
Grossly, the surgical specimen consisted of pancreatic tail tissue, 10 cm × 4 cm × 3.5 cm, and unremarkable spleen tissue (146 gm). A well-circumscribed gray-brown nodular mass, 3.8 cm × 3.2 cm × 2.2 cm, was found in the pancreatic parenchyma. On serial cuts, the nodular mass clearly showed a red-brown, hemorrhagic, centrally necrotic heterogenous part and a gray-white, focally hemorrhagic solid part (Figure 2). A thin fibrous band was present between these two parts. No gross invasion to spleen, large vessels or resection margins was found.
Figure 2 Gross examination showing a well-circumscribed tumor with a central fibrous band (arrows) separating the right exocrine and the left endocrine parts.
The microscopic sections showed pancreatic tissue with a partially encapsulated tumor composed of two distinctly separated, exocrine and endocrine components (Figure 3A). The two components did not grow into each other and were completely separated by a small band of fibrous tissue and some residual, atrophic, benign exocrine glands. The endocrine part, up to 1.8 cm in diameter and occupying more than 40% of the pancreatic tumor, was well-circumscribed, completely enclosed by fibrous tissue and composed of uniform tumor cells containing small, round, monotonous nuclei and pale or mildly acidophilic cytoplasm (Figure 3B). These cells were arranged in gyriform or trabecullar patterns divided by slender fibrous connective tissue and rich vascular stroma. Neither mitotic figures nor cellular atypia was found. No evidence of necrosis, extrapancreatic spread or vascular invasion was present. Mucin and congo red stains were negative. On immunohistochemical (IHC) staining, the tumor cells were diffusely and strongly positive for chromogranin A (Figure 3C), synaptophysin (Figure 3D) and glucagon (Figure 3E). No expression of CA19-9 (Figure 3F), p53, Bcl-2, insulin, gastrin, vasointestinal peptide was demonstrated in the tumor. Ki-67 + cells were less than 0.5%. The exocrine component, a poorly-differentiated ductal adenocarcinoma, showed bizarre and hyperchromatic cells containing pleomorphic darkly staining nuclei, some mitoses and pale or acidophilic cytoplasm (Figure 3G). Scattered anaplastic nuclei were also found. These tumor cells were arranged in dilated ductal structures, small glands, cellular files or single cells, with large areas of necrosis and hemorrhage. The exocrine component showed focal invasion of peripancreatic soft tissue. The spleen and 9 peripancreatic lymph nodes were free of tumor. Mucin secretion was demonstrated by mucicarmine and periodic acid-Schiff with diastase stains. On immunohistochemical staining, this component was strongly positive for CA19-9 (Figure 3H), and negative for chromogranin A (Figure 3C), synaptophysin (Figure 3D), glucagon (Figure 3E), insulin, gastrin, vasointestinal peptide and Bcl-2. Ki-67 + cells were more than 25%. More than 55% of the ductal adenocarcinoma had strong intranuclear accumulation of p53 protein. In this case, the exocrine and endocrine components were clearly separated and different from each other in the single tumor. No collision or intermixing area could be found. With no other endocrine manifestations and focal lesion found in the thyroid and adrenal glands, MEN type 1 was not considered. Finally, a solitary concomitant endocrine tumor and ductal adenocarcinoma of the pancreas was diagnosed.
Figure 3 Microscopic features of solitary concomitant endocrine tumor and ductal adenocarcinoma of pancreas.
A: Low-power view showing ductal adenocarcinoma (left) and endocrine tumor (right) with a fibrous band (central) clearly demarcating the two components (HE × 40); B: Pancreatic endocrine tumor composed of monotonous small, round tumor cells arranged in gyriform or trabecullar patterns, marginated by a fibrous wall (right) (HE × 100); C-E: Pancreatic endocrine tumor (right) showing positive expression while ductal adenocarcinoma (left) showing negative expression of chromogranin A, synaptophysin and glucagon (IHC × 40); F: Pancreatic endocrine tumor (left) showing negative expression while residual benign pancreatic glands (right) showing positive expression of carbohydrate antigen 19-9 (CA19-9) (IHC × 100); G and H: Higher magnifications of ductal adenocarcinoma showing bizarre pleomorphic glands (HE × 200) and immunoreactive to CA19-9 (IHC × 200).
To the best of our knowledge, this is the first case of solitary concomitant PET and ductal adenocarcinoma of the pancreas reported in the English literature. Ballas et al reported a case of mixed exocrine-endocrine tumor of the pancreas showing two distinct populations of tumor cells. Most parts of these two components were separated but focally showed a collision type of growth, with two different components growing into one another. Goh and colleagues reported three cases of concomitant intraductal papillary mucinous neoplasm (IPMN) of the pancreas and pancreatic endocrine neoplasm. The sizes of the endocrine part were small (2, 5 and 8 mm) and well-circumscribed, isolated and nonfunctional. However, the morphology of all three exocrine components was not indicative of classical invasive ductal carcinoma as the present one.
Many reports have discussed the histogenesis of the association between exocrine and endocrine neoplasms of the pancreas[2,3,11,12]. Leteurtre et al reported a case of mixed ductal-endocrine carcinoma of the pancreas and supported the hypothesis of a common endodermal histogenesis for ductal and endocrine cells. Chatelain and colleagues also suggested that these tumors probably arise from a totipotent endodermal cell distributed in the pancreatic ducts and islets. Marrache et al presented 6 patients with associated IPMN and PET, and suggested that these tumors may arise from a common progenitor cell or due to differentiation from one cell type to the other. Morikane et al presented a small glucagonoma of the pancreas with evident ductular and tubular structures and supported the hypothesis that pancreatic endocrine tumors originate in the ductular epithelium. In the report of Cho et al, the tumor cells of a mixed acinar-endocrine carcinoma of the pancreas showed amphicrine differentiation, with one cell type harboring both exocrine and endocrine markers simultaneously, indicating that a close histogenetic relationship exists between pancreatic exocrine and endocrine cells. Pour et al concluded that pancreatic cancer derives from pancreatic stem cells distributed within ductal trees and islets. According to the previous literature, it seems reasonable to hypothesize that associated exocrine and endocrine neoplasms of the pancreas arise from totipotent pancreatic stem cells, which reside in the pancreatic duct and islets. Under certain stimulation, the stem cells differentiate and give rise to exocrine and endocrine primitive cells. The exocrine primitive cells further differentiate into ductal and acinar cells. According to the proposed differentiation pathway, we hypothesize that the amphicrine type arises from early stem cells that proliferate into a neoplasm before differentiating into endocrine and exocrine cells (Figure 4). Thus, the amphicrine type, as in the case reported by Cho et al, contains only one cell type that has both exocrine and endocrine features. When the stem cells begin to differentiate into primitive exocrine and endocrine cells, three types of histological patterns may occur: mixed, collision and solitary concomitant. In the mixed type, the exocrine and endocrine cells are intimately intermixed together. Most reported cases of mixed exocrine and endocrine tumor of the pancreas are examples of this type[2-7]. The collision type, as in the case reported by Ballas et al, shows the endocrine part at one end and the exocrine part at the other end, with an intermixed central zone. The solitary concomitant type, first presented in our case, shows a single tumor composed of distinctly separate exocrine and endocrine components, with a dividing fibrous band found between the two parts. The last type is a multiple concomitant type that contains isolated exocrine and endocrine tumors simultaneously. The three cases reported by Goh et al can be classified as the early ones of this latter type.
Figure 4 Five types of pancreatic neoplasm with combined exocrine and endocrine features.
Because the present tumor contained both pancreatic endocrine tumor and exocrine carcinoma, we tried to consider these two parts together when discussing the prognosis of this patient. No evidence of metastasis was found at abdominal CT, whole body positron emission tomography scan and during surgery. The size of the present endocrine tumor was 1.8 cm. The microscopic features showed scarce mitoses and less than 0.5% Ki-67+ cells. Neither extrapancreatic spread nor vascular invasion was identified. According to criteria of the WHO Committee for Histological Typing of Endocrine Tumors, the present endocrine tumor was classified as a well-differentiated endocrine tumor with benign behavior. In the previous literature and papers presenting cases of mixed exocrine and endocrine carcinoma, the authors suggested that the prognosis depends mainly on the stage of ductal carcinoma[2,8,9]. We cannot be certain that the prognosis of our case depends on the ductal carcinoma component because this is not a case of mixed exocrine and endocrine carcinoma of the pancreas as previously presented. Further study with more cases is necessary.
Chatelain et al presented a case of mixed ductal-pancreatic polypeptide-cell carcinoma of the pancreas. In their study, the endocrine cells were not immunoreactive to p53 and Bcl-2, but the exocrine ductal cells were stained strongly positive, suggesting that over-expression of p53 and Bcl-2 plays a major role in neoplastic progression of the ductal component. We performed p53 and Bcl-2 immunostains in the present case. The endocrine part was negative for p53 and more than 55% of exocrine neoplastic cells showed strong intranuclear accumulation. However, both the endocrine and exocrine parts were negative for Bcl-2. The role of p53 and Bcl-2 in tumor histogenesis still needs further investigation.
Glucagonomas are rare and only represent about 10% of all functioning pancreatic tumors[15-17]. Cases without typical symptoms usually remain undiagnosed, resulting in long-term medical waste, and mental and physical suffering of the patients[18,19]. In our case, the patient only presented with DM and body weight loss and did not satisfy the criteria of glucagonoma syndrome. However, it was not certain whether the alpha-cell tumor plays a role in the manifestation of DM or not. In a recent study of pancreatic cancer-associated DM, Pannala et al concluded that pancreatic cancer is a powerful diagnostic state and new-onset DM is likely induced by the tumor. Under this viewpoint, the adenocarcinoma of our case may be closely related to the poor control of DM, especially because the patient did not develop glucagonoma syndrome. In short, we suggest that, in cases of type II DM occurring in middle-aged patients, the development of uncontrolled hyperglycemia should raise clinical suspicion of glucagonoma and/or pancreatic cancer. In this situation, further survey including pancreatic hormones and tumor marker profile is suggested.
In conclusion, combined pancreatic endocrine and exocrine tumors are rare. We have reported the first case of solitary concomitant pancreatic endocrine tumor and ductal adenocarcinoma. We suggest a classification system of tumor histogenesis for this group of tumors, including amphicrine, mixed, collision, solitary concomitant and multiple concomitant. Further investigation of more cases of this rare entity is still necessary.
Peer reviewers: Robert Jensen, MD, Digestive Disease Branch, National Institutes of Health, Building 10, Rm 9C-103, Bethesda, MD 20892, United States; Rupjyoti Talukdar, MD, Department of Gastroenterology and Hepatology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, United States
S- Editor Wang JL L- Editor Wang XL E- Editor Ma WH
Heitz PU, Komminoth P, Perren A, Klimstra DS, Dayal Y, Bordi C, Lechago J, Centeno BA, Kloppel G. Pancreatic endocrine tumours: introduction.World Health Organization Classification of Tumours. Pathology & Genetics of Tumours of Endocrine Organs. Lyon: International Agency for Research on Cancer; 2003;177-182.
Chatelain D, Parc Y, Christin-Maitre S, Parc R, Flejou JF. Mixed ductal-pancreatic polypeptide-cell carcinoma of the pancreas.Histopathology. 2002;41:122-126.
Leteurtre E, Brami F, Kerr-Conte J, Quandalle P, Lecomte-Houcke M. Mixed ductal-endocrine carcinoma of the pancreas: a possible pathogenic mechanism for arrhythmogenic right ventricular cardiomyopathy.Arch Pathol Lab Med. 2000;124:284-286.
Ohike N, Kosmahl M, Klöppel G. Mixed acinar-endocrine carcinoma of the pancreas. A clinicopathological study and comparison with acinar-cell carcinoma.Virchows Arch. 2004;445:231-235.
Ogawa T, Isaji S, Yabana T. A case of mixed acinar-endocrine carcinoma of the pancreas discovered in an asymptomatic subject.Int J Pancreatol. 2000;27:249-257.
Schron DS, Mendelsohn G. Pancreatic carcinoma with duct, endocrine, and acinar differentiation. A histologic, immunocytochemical, and ultrastructural study.Cancer. 1984;54:1766-1770.
Tanakaya K, Teramoto N, Konaga E, Takeuchi H, Yasui Y, Takeda A, Yunoki Y, Murakami I. Mixed duct-acinar-islet cell tumor of the pancreas: report of a case.Surg Today. 2001;31:177-179.
Capella C, Oberg K, Papotti M, Valante M, Bordi C. Mixed exocrine-endocrine carcinomas.World Health Organization Classification of Tumours. Pathology & Genetics of Tumours of Endocrine Organs. Lyon: International Agency for Research on Cancer; 2004;205-206.
Ballas KD, Rafailidis SF, Demertzidis C, Alatsakis MB, Pantzaki A, Sakadamis AK. Mixed exocrine-endocrine tumor of the pancreas.JOP. 2005;6:449-454.
Goh BK, Ooi LL, Kumarasinghe MP, Tan YM, Cheow PC, Chow PK, Chung YF, Wong WK. Clinicopathological features of patients with concomitant intraductal papillary mucinous neoplasm of the pancreas and pancreatic endocrine neoplasm.Pancreatology. 2006;6:520-526.
Marrache F, Cazals-Hatem D, Kianmanesh R, Palazzo L, Couvelard A, O'Toole D, Maire F, Hammel P, Levy P, Sauvanet A. Endocrine tumor and intraductal papillary mucinous neoplasm of the pancreas: a fortuitous association?Pancreas. 2005;31:79-83.
Morikane K, Kimura W, Inoue S, Muto T. A small glucagonoma of the pancreas with evident ductular and tubular structures.J Gastroenterol. 1997;32:562-565.
Cho KJ, Kim JY, Lee SS, Khang SK, Kim CW. Mixed acinar-endocrine carcinoma of the pancreas--a case report.J Korean Med Sci. 1996;11:188-192.
Pour PM, Schmied B. The link between exocrine pancreatic cancer and the endocrine pancreas.Int J Pancreatol. 1999;25:77-87.
Klimstra DS, Perren A, Oberg K, Komminoth P, Bordi C. Nonfunctioning tumours and microadenomas.World Health Organization Classification of Tumours. Pathology & Genetics of Tumours of Endocrine Organs. Lyon: International Agency for Research on Cancer; 2004;201-204.
Heitz PU, Kasper M, Polak JM, Klöppel G. Pancreatic endocrine tumors.Hum Pathol. 1982;13:263-271.
Kloppel G, Komminoth P, Perren A, Oberg K, Matias-Guiu X, Heitz PU. Glucagonoma.World Health Organization Classification of Tumours. Pathology & Genetics of Tumours of Endocrine Organs. Lyon: International Agency for Research on Cancer; 2004;187-188.
Zhang M, Xu X, Shen Y, Hu ZH, Wu LM, Zheng SS. Clinical experience in diagnosis and treatment of glucagonoma syndrome.Hepatobiliary Pancreat Dis Int. 2004;3:473-475.